Ono and Takeda receive an approval for Opdivo (nivolumab) and Cabometyx (cabozantinib) combination therapy in Japan for treatment of unresectable or metastatic renal cell carcinoma

Ono Pharmaceutical

25 August 2021 - Ono Pharmaceutical and Takeda today announced that the companies have received an approval for combination therapy of Ono’s Opdivo (nivolumab) and Takeda’s Cabometyx (cabozantinib s-malate) tablets which Takeda has licensed from Exelixis, in combination therapy for the treatment of unresectable or metastatic renal cell carcinoma, for a partial change in approved items of the manufacturing and marketing approval.

This approval is based on results from the global, multi-center, randomised, open-label Phase 3 CheckMate-9ER study, evaluating Opdivo and Cabometyx combination therapy versus sunitinib alone in patients with previously untreated advanced or metastatic renal cell carcinoma.

Read Ono Pharmaceutical press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Japan